BCIQ Profiles

Company Profile Report
0324 Reg QT
BioCentury & Getty Images

Regulation

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

Mar 25, 2021 | 12:54 AM GMT

Twist Bioscience Corp. (NASDAQ:TWST) said it and partner Biotia Inc. received emergency use authorization from FDA for the first hybridization capture-based next-generation sequencing SARS-CoV-2 assay. The SARS-CoV-2 NGS Assay can sequence and surveil the evolution

Read the full 673 word article

How to gain access

Continue reading with a
two-week free trial.